AIM ImmunoTech Inc

Insider buying of AIM ImmunoTech’s Series G preferred and warrants shows confidence in a rights offering aimed at funding R&D, while balancing dilution risks and clinical milestones for investors.

Insider buying at a steeply discounted price signals hidden confidence in AIM ImmunoTech’s immunotherapy pipeline, hinting at potential upside despite a 90% share drop.